Correlation Between BriaCell Therapeutics and Tharimmune

Can any of the company-specific risk be diversified away by investing in both BriaCell Therapeutics and Tharimmune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BriaCell Therapeutics and Tharimmune into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between BriaCell Therapeutics Corp and Tharimmune, you can compare the effects of market volatilities on BriaCell Therapeutics and Tharimmune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BriaCell Therapeutics with a short position of Tharimmune. Check out your portfolio center. Please also check ongoing floating volatility patterns of BriaCell Therapeutics and Tharimmune.

Diversification Opportunities for BriaCell Therapeutics and Tharimmune

0.6

Correlation Coefficient

BriaCell Therapeutics  Tharimmune

Poor diversification

The 3 months correlation between BriaCell and Tharimmune is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding BriaCell Therapeutics Corp and Tharimmune in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tharimmune and BriaCell Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BriaCell Therapeutics Corp are associated (or correlated) with Tharimmune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tharimmune has no effect on the direction of BriaCell Therapeutics i.e., BriaCell Therapeutics and Tharimmune go up and down completely randomly.

Pair Corralation between BriaCell Therapeutics and Tharimmune

Assuming the 90 days horizon BriaCell Therapeutics Corp is expected to under-perform the Tharimmune. In addition to that, BriaCell Therapeutics is 2.78 times more volatile than Tharimmune. It trades about -0.15 of its total potential returns per unit of risk. Tharimmune is currently generating about -0.15 per unit of volatility. If you would invest  221.00  in Tharimmune on December 1, 2024 and sell it today you would lose (78.00) from holding Tharimmune or give up 35.29% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	93.33%
Values	Daily Returns

BriaCell Therapeutics Corp  vs.  Tharimmune

BriaCell Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days BriaCell Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Tharimmune

Risk-Adjusted Performance

Very Weak

Over the last 90 days Tharimmune has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with BriaCell Therapeutics and Tharimmune

The main advantage of trading using opposite BriaCell Therapeutics and Tharimmune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BriaCell Therapeutics position performs unexpectedly, Tharimmune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will offset losses from the drop in Tharimmune's long position.

The idea behind BriaCell Therapeutics Corp and Tharimmune pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.